Is there a difference between levodopa/dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The honeymoon study

European Neurology

Volumn 61, Issue 2, 2009, Pages 69-75

  Destée, Alain ^a,b   Rérat, Karin ^c,d   Bourdeix, Isabelle ^c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

^c NOVARTIS PHARMA K K   (Japan)

^d Clinical Research and Development   (France)

Author keywords

Dose fractionation; Dyskinesia; Entacapone; Levodopa; Parkinson's disease; Symptom re emergence due to wearing off

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; PLACEBO; SELEGILINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; FLATULENCE; FOLLOW UP; FRACTIONATION; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PARKINSONISM; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE COLOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CATECHOLS; DOPA DECARBOXYLASE; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; NITRILES; PARKINSON DISEASE;

EID: 56749184082     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000177938     Document Type: Article

References (11)

1. Ahlskog JE, Muenter MD: Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
2. Fahn S; and the Parkinson Study Group: Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 2005;252(suppl 4):IV37-IV42.
3. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group: Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003;74:1071-1079.
4. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group: Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-255.
5. Parkinson Study Group: Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
6. Rinne UK, Larsen JP, Siden A, Worm-Petersen J: Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314.
7. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M; NOMESAFE Study Group: The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003;10:137-146.
8. Jankovic J: Management of motor side effects of chronic levodopa therapy. Clin Neuropharmacol 1982;5(suppl 1):S19-S28.
9. Silver DE: Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®). Expert Rev Neurother 2004;4:589-599.
10. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-1310.
11. Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group: Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 2001;8:53-60.